Nebenwirkungen · Columvi
Columvi 2.5 mg concentrate for solution for infusion Columvi 10 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 22
HOS-149244 · Präparat HOS-100012
Among the 11 patients who experienced Grade ≥ 2 tumour flare, 2 patients (18.2%) received analgesics, 6 patients (54.5%) received corticosteroids and analgesics including morphine derivatives, 1 patient (9.1%) received corticosteroids and anti-emetics, and 2 patients (18.2%) did not require treatment. All tumour flare events resolved except in one patient with a Grade ≥ 2 event. No patients discontinued treatment due to tumour flare.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T13:00:00Z · SHA-256 2c5f4e2a70d7830059221b97eb832e6bb8ef846ec2df0243e5154b9f1ae1a38f · Passage 1d13d4a49d7d348876e28ff031c5530c50fcd5a90af64de198204915989eb298 · Zeichen 26856–27293 im Abschnitt